Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, recently announced it has entered into a 15-year lease agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility. The facility, to be built by McMaster and equipped and validated by Fusion, will be designed to support the manufacturing of the company's growing pipeline of targeted alpha therapies (TATs). Fusion expects the manufacturing facility to be operational by early 2024.

To read more please visit:

https://ir.fusionpharma.com/2021-06-02-Fusion-Pharmaceuticals-Enters-into-Agreement-to-Build-Radiopharmaceutical-Manufacturing-Facility

Source: Fusion Pharmaceuticals